stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Total debt
Novo Nordisk A/S's total debt at the end of fiscal 2025 was $19.8B, up 33.0% from $14.9B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $21.8B. Over the past ten years it has ranged from $34.0M (fiscal 2016) to $19.8B (fiscal 2025) — the current reading is the highest in ten years. Novo Nordisk A/S ranks 12th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $19.8B | 33.03% |
| FY2024 | $14.9B | 280.08% |
| FY2023 | $3.9B | 7.40% |
| FY2022 | $3.7B | (13.88%) |
| FY2021 | $4.2B | 167.20% |
| FY2020 | $1.6B | 136.09% |
| FY2019 | $672.0M | 753.41% |
| FY2018 | $78.7M | (69.40%) |
| FY2017 | $257.3M | 656.17% |
| FY2016 | $34.0M | (78.69%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $21.8B | (4.88%) |
| Mar 2026 | $22.9B | 15.62% |
| Dec 2025 | $19.8B | 25.09% |
| Sep 2025 | $15.9B | 4.98% |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| NVS Novartis AG compare | $46.3B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| GSK GSK PLC Sponsored ADR compare | $31.9B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S | $21.8B |
| SNY Sanofi compare | $20.7B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement